Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2025-06-30 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Prescient Therapeutics Launches Share Purchase Plan for $7m 5 pages 165.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement by Prescient Therapeutics regarding a Share Purchase Plan (SPP) to raise $7 million. It details the terms of the SPP, including the share price, discount to VWAP, record date, timetable for the offer, and use of proceeds. It also includes information about a shareholder briefing and contact details. The document does not contain financial statements, audit information, or detailed financial results. It is not a report but an announcement of a capital raising activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 12,000 characters, indicating it is a full announcement rather than a brief notice or a report publication announcement.
2025-06-30 English
Proposed issue of securities - PTX 6 pages 21.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a securities purchase plan (SPP) by Prescient Therapeutics Limited. It includes specifics such as the number of securities to be issued, offer price, record date, offer closing date, issue date, fees, and purpose of the funds raised. The content is focused on the announcement and details of a new securities issuance under ASX Listing Rules, not a financial report or earnings release. The document length is 8854 characters, which is substantive and contains detailed information about the capital raising event. Therefore, this document fits the category of Capital/Financing Update (CAP).
2025-06-30 English
Change of Registered Office and Principal Place of Business 3 pages 138.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change of the company's registered office and principal place of business. It includes company background information and product descriptions but does not contain any financial statements, detailed financial performance data, or regulatory filings. There is no indication of this being an annual report, interim report, earnings release, or any other detailed financial or regulatory document. The document is relatively short (9234 characters) and serves as a formal notification to the market in compliance with ASX Listing Rule 3.14. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-06-01 English
PTX Updated Investor Presentation 38 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Briefing on the back of 1st patient dosing' and includes detailed information about the company's clinical trial progress, drug development pipeline, and technology platforms. It mentions a live and online investor briefing event and provides a link for registration. The content is primarily a presentation-style update aimed at investors, focusing on the company's strategy, clinical trial design, and market potential. There are no financial statements, regulatory certifications, or voting results. The document is lengthy (15,000 characters) and contains detailed presentation content rather than just an announcement or a brief summary. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. Therefore, the appropriate classification is Investor Presentation (IP).
2025-05-28 English
First Patient dosed for PTX-100 Phase 2a Study 4 pages 207.7KB
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the dosing of the first patient in a Phase 2a clinical study for a drug candidate (PTX-100) by Prescient Therapeutics Limited. It includes details about the study design, drug mechanism, and upcoming investor briefing. There are no financial statements, regulatory filings, or detailed financial data. The document is an announcement of a clinical trial milestone and an investor update rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a call transcript or management report. The content is primarily an operational update and investor communication about clinical progress and upcoming briefing. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to development progress and investor communication about a clinical trial milestone, which is often grouped under capital/financing updates in biotech companies' filings.
2025-05-26 English
Prescient Therapeutics - Investor Briefing 23 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Briefing May 2025' and contains detailed information about the company's drug development pipeline, clinical trial phases, market opportunities, and strategic milestones. It includes forward-looking statements, clinical data, market analysis, and development plans. The content is presented as a detailed presentation aimed at investors, focusing on financial prospects, clinical progress, and strategic positioning rather than being a formal regulatory filing or financial report. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. The document is too long and detailed to be a simple announcement or regulatory filing. It fits the description of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position.
2025-05-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.